LX1033 Approval Status
FDA Approved: No
Brand name: LX1033
Company: Lexicon Pharmaceuticals, Inc.
Treatment for: Irritable Bowel Syndrome
LX1033 is an oral tryptophan hydroxylase inhibitor in development for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).
Development Status and FDA Approval Process for LX1033
|Dec 3, 2013||Lexicon Completes Phase 2 Study of LX1033 in IBS-D|
|Dec 17, 2012||Lexicon's Drug Candidate For Irritable Bowel Syndrome (LX1033) Receives Fast Track Status From The FDA|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.